Arrowhead Pharmaceuticals Inc logo

ARWR - Arrowhead Pharmaceuticals Inc Share Price

$26.12 -0.8  -2.9%

Last Trade - 03/04/20

Mid Cap
Market Cap £2.17bn
Enterprise Value £1.76bn
Revenue £133.4m
Position in Universe 1273rd / 6308
Unlock ARWR Revenue
Relative Strength (%)
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


ARWR Revenue Unlock ARWR Revenue

Net Income

ARWR Net Income Unlock ARWR Revenue

Normalised EPS

ARWR Normalised EPS Unlock ARWR Revenue

PE Ratio Range

ARWR PE Ratio Range Unlock ARWR Revenue

Dividend Yield Range

ARWR Dividend Yield Range Unlock ARWR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ARWR EPS Forecasts Unlock ARWR Revenue
Profile Summary

Arrowhead Pharmaceuticals, Inc., formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company's therapies trigger the RNA interference mechanism to induce knockdown of target genes. The Company is focused on developing drugs for diseases with a genetic basis, characterized by the overproduction of one or more proteins. The Company's preclinical pipeline of RNA interference (RNAi) therapeutics includes both subcutaneously administered liver-targeted candidates and extra-hepatic candidates. The Company's pre-clinical-stage drug candidates include ARO-HBV, ARO-AAT, ARO-LPA, ARO-AMG1, ARO-F12 and ARO-HIF2. ARO-HBV is an RNAi therapeutic candidate for the treatment of chronic hepatitis B infection. ARO-AAT is a therapeutic candidate for the treatment of liver disease associated with Alpha-1 Antitrypsin Deficiency.

Last Annual September 30th, 2019
Last Interim December 31st, 2019
Incorporated February 13, 2001
Public Since December 14, 1993
No. of Shareholders: 112
No. of Employees: 134
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P 400 Mid Cap , Nasdaq Composite , S&P Composite 1500 ,
Exchange NASDAQ Global Select Market
Shares in Issue 101,654,477
Free Float (0.0%)
Eligible for
ARWR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for ARWR
Upcoming Events for ARWR
Thursday 9th April, 2020
Arrowhead Pharmaceuticals Inc at Wells Fargo Biotech Corporate Access Day - San Francisco (Virtual)
Wednesday 6th May, 2020 Estimate
Q2 2020 Arrowhead Pharmaceuticals Inc Earnings Release
Monday 3rd August, 2020 Estimate
Q3 2020 Arrowhead Pharmaceuticals Inc Earnings Release
Similar to ARWR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.